PErmanent visual loss and cerebrovascular accidents in giant cell arteritis -: Predictors and response to treatment

被引:0
|
作者
González-Gay, MA
Blanco, R
Rodríguez-Valverde, V
Martínez-Taboada, VM
Delgado-Rodriguez, M
Figueroa, M
Uriarte, E
机构
[1] Hosp Univ M Valdecilla, Rheumatol Serv, Santander 39008, Spain
[2] Hosp Xeral Calde, Lugo, Spain
[3] Univ Cantabria, E-39005 Santander, Spain
[4] Hosp Nuestra Senora de Aranzazu, San Sebastian, Spain
来源
ARTHRITIS AND RHEUMATISM | 1998年 / 41卷 / 08期
关键词
D O I
10.1002/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To assess the features and therapeutic response of visual manifestations and cerebrovascular accidents (CVA) in giant cell (temporal) arteritis (GCA) and to identify the predictors for permanent visual loss (VL) and CVA in GCA. Methods. Two hundred thirty-nine patients with biopsy-proven GCA were included in a retrospective multicenter study. Data on demographic, clinical, and laboratory features were collected. The predictors were identified by a forward stepwise nonconditional logistic regression analysis. Results. Visual involvement was observed in 69 patients, and 34 had permanent VL. The diagnostic delay since the onset of visual symptoms was longer in the 11 patients with bilateral VL. The interval to involvement of the second eye was 5 days. The predictors of permanent VL were transient VL, jaw claudication, normal levels of liver enzymes, and absence of constitutional syndrome. Partial improvement of visual acuity was observed in 8 patients. After adjustment for the treatment regimen (intravenous pulse methylprednisolone versus oral prednisone), early treatment (within the first day of VL) was the only predictor of improvement; CVA, observed in 8 patients, involved the vertebral-basilar territory in 4, CVA was more frequent in patients,vith visual symptoms, appearing shortly after VL (median 7 days) and despite appropriate therapy. Predictors of CVA were permanent VL and jaw claudication. Conclusion. In GCA, the risk of permanent VL is increased in patients with transient VL and/or jaw claudication, and decreased in those with elevated liver enzyme levels and/or constitutional syndrome. Partial therapeutic success is more probable if treatment is started within the first day of VL, CVA is more likely in patients with permanent VL and/or jaw claudication, often developing despite appropriate corticosteroid therapy.
引用
收藏
页码:1497 / 1504
页数:8
相关论文
共 50 条
  • [21] Characteristics of cerebrovascular accidents at time of diagnosis in a series of 98 patients with giant cell arteritis
    Zenone, Thierry
    Puget, Marie
    RHEUMATOLOGY INTERNATIONAL, 2013, 33 (12) : 3017 - 3023
  • [22] Cerebrovascular accidents in giant cell arteritis: prevalence and predictive factors from the ARTESER registry
    Martin-Gutierrez, Adrian
    Molina-Collada, Juan
    Dominguez-alvaro, Marta
    Melero-Gonzalez, Rafael B.
    Fernandez-Fernande, Elisa
    Silva-Diaz, Maite
    Valero, Jesus Alejandro
    Gonzalez, Ismael
    Martin, Julio Sanchez
    Narvaez, Javier
    Calvo, Itziar
    Aldasoro, Vicente
    Alcazar, Lydia Abasolo
    Loricera, Javier
    Ruiz-Roman, Alberto
    Castaneda, Santos
    Molina-Almela, Clara
    Villar, Maria Alcalde
    Mas, Antonio Juan
    Blanco, Ricardo
    ARTESER Project Collaborat Grp, Clara Moriano
    RHEUMATOLOGY, 2025,
  • [23] Characteristics of cerebrovascular accidents at time of diagnosis in a series of 98 patients with giant cell arteritis
    Thierry Zenone
    Marie Puget
    Rheumatology International, 2013, 33 : 3017 - 3023
  • [24] Characterization of visual manifestations and identification of risk factors for permanent vision loss in patients with giant cell arteritis
    Baalbaki, Hussein
    Jalaledin, Darya
    Lachance, Catherine
    Febrer, Guillaume
    Rheaume, Maxime
    Makhzoum, Jean-Paul
    CLINICAL RHEUMATOLOGY, 2021, 40 (08) : 3207 - 3217
  • [25] Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis
    Font, C
    Cid, MC
    CollVinent, B
    LopezSoto, A
    Grau, JM
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (02): : 251 - 254
  • [26] Characterization of visual manifestations and identification of risk factors for permanent vision loss in patients with giant cell arteritis
    Hussein Baalbaki
    Darya Jalaledin
    Catherine Lachance
    Guillaume Febrer
    Maxime Rhéaume
    Jean-Paul Makhzoum
    Clinical Rheumatology, 2021, 40 : 3207 - 3217
  • [27] Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients with Giant Cell Arteritis
    Baalbaki, Hussein
    Jalaledin, Darya
    Lachance, Catherine
    Makhzoum, Jean-Paul
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [28] Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients With Giant Cell Arteritis
    Baalbaki, Hussein
    Jalaledin, Darya
    Lachance, Catherine
    Makhzoum, Jean-Paul
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1147 - 1147
  • [29] ATYPICAL VISUAL-LOSS IN GIANT-CELL ARTERITIS
    THYSTRUP, J
    KNUDSEN, GM
    MOGENSEN, AM
    FLEDELIUS, HC
    ACTA OPHTHALMOLOGICA, 1994, 72 (06): : 759 - 764
  • [30] An unusual cause of visual loss in a patient with giant cell arteritis
    Shakir, Rebecca
    Steuer, Alan
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2013, 16 (03) : 359 - 360